Isoniazid: Difference between revisions
(Redirected page to INH Toxicity) |
ClaireLewis (talk | contribs) (Removed redirect to INH toxicity) Tag: Removed redirect |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | |||
*Type: Anti-[[TB]] | |||
*Dosage Forms: | |||
*Routes of Administration: PO, IM | |||
*Common Trade Names: INH | |||
==Adult Dosing== | |||
*Typically 5 mg/kg (or 300mg) daily | |||
==Pediatric Dosing== | |||
* ≤40 kg: 10-15 mg/kg daily, maximum 300mg/dose | |||
*>40kg: 5 mg/kg daily max 300mg/dose | |||
==Special Populations== | |||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | |||
*Category A | |||
===Lactation risk=== | |||
*Considered compatible with breast feeding<ref> World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/</ref> | |||
===Renal Dosing=== | |||
*No adjustment | |||
===Hepatic Dosing=== | |||
*No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease | |||
==Contraindications== | |||
*Allergy/hypersensitivity to class/drug | |||
*Prior history of hepatic injury or severe adverse reaction to isoniazid | |||
*Acute liver disease | |||
==Adverse Reactions== | |||
===Serious=== | |||
===Common=== | |||
*Increased serum transaminases | |||
==Pharmacology== | |||
*Half-life: Fast acetylators: 30 to 100 minutes, slow acetylators: 2 to 5 hours | |||
*Metabolism: Hepatic | |||
*Excretion: Mostly urine | |||
==Mechanism of Action== | |||
*Inhibits synthesis of mycoloic acids (essential bacterial cell wall component) | |||
==Comments== | |||
==See Also== | |||
*[[Isoniazid toxicity]] | |||
==References== | |||
*Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195. | |||
*Uptodate | |||
<references/> | |||
[[Category:Pharmacology]] | |||
Latest revision as of 15:31, 8 February 2021
Administration
- Type: Anti-TB
- Dosage Forms:
- Routes of Administration: PO, IM
- Common Trade Names: INH
Adult Dosing
- Typically 5 mg/kg (or 300mg) daily
Pediatric Dosing
- ≤40 kg: 10-15 mg/kg daily, maximum 300mg/dose
- >40kg: 5 mg/kg daily max 300mg/dose
Special Populations
Pregnancy Rating
- Category A
Lactation risk
- Considered compatible with breast feeding[1]
Renal Dosing
- No adjustment
Hepatic Dosing
- No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease
Contraindications
- Allergy/hypersensitivity to class/drug
- Prior history of hepatic injury or severe adverse reaction to isoniazid
- Acute liver disease
Adverse Reactions
Serious
Common
- Increased serum transaminases
Pharmacology
- Half-life: Fast acetylators: 30 to 100 minutes, slow acetylators: 2 to 5 hours
- Metabolism: Hepatic
- Excretion: Mostly urine
Mechanism of Action
- Inhibits synthesis of mycoloic acids (essential bacterial cell wall component)
Comments
See Also
References
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
- Uptodate
- ↑ World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/